Clinical trial
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
NCT00252850 · Sangamo Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00252850 |
|---|---|
| Title | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease |
| Official title | A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease |
| Lead sponsor | Sangamo Therapeutics, Industry |
| Collaborators | Ceregene Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Genetic |
| Interventions | CERE-120: AAV2-NTN |
| Enrollment | 12 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Nov 15, 2005 |
| Last update posted | Nov 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: